Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 ASCRS

Sight Sciences announced that two of its proprietary glaucoma and dry eye technologies, the Omni Surgical System and the TearCare System, will be featured in oral presentations and one poster at this year's ASCRS annual meeting in San Diego. The Omni Surgical System technology facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma. The TearCare System technology for dry eye enables an interventional eyelid procedure for diseased meibomian glands and is indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction.

"As the largest annual gathering for anterior segment surgeons, ASCRS provides an important opportunity to share important clinical research and collaborate with existing and future customers," said Paul Badawi, CEO and co-founder of Sight Sciences. "This year is truly unique given the breadth and sheer strength of our clinical data across our product portfolio. For example, one presentation includes a data readout from a landmark real-world data analysis extracted directly from the IRIS Registry, the ophthalmology community's largest clinical results database, and compares the relative clinical outcomes from procedures performed with OMNI Surgical System technology versus those performed with commonly used MIGS implants and cataract surgery alone. Another presentation will show the clinical outcomes of the standalone outflow restorative procedure enabled by Omni Surgical System technology in pseudophakic patients who previously received canal implants but whose intraocular pressure was no longer under control."

Oral Presentations: Omni Surgical System

• Glaucoma Medication Use in Patients with a Mild Glaucoma Severity After Receiving MIGS: An Academy IRIS Registry Analysis oral presentation by Michael Mbagwu, MD.
• Canaloplasty and Trabeculotomy in POAG Refractory to Medication and Prior Trabecular Microbypass Stenting oral presentation by Daniel Terveen, MD.
• Canaloplasty and Trabeculotomy with Cataract Surgery in Eyes with Primary Open-Angle Glaucoma (POAG): Two Year Outcomes from the ROMEO Study oral presentation by Blake Williamson, MD.

"Sight Sciences has devoted tremendous effort into demonstrating the safety and effectiveness of outflow procedures enabled by its Omni Surgical System technology," Daniel Terveen, MD, of Vance Thompson Vision in Sioux Falls, South Dakota, said in a company news release. "Patients uncontrolled by medication and a prior trabecular bypass stent implantation would once have been candidates for far more invasive trabeculectomy and tube shunts. Our study found that the less invasive Omni Surgical System technology creates an important procedural option that provides IOP control and the avoidance or delay of traditional invasive glaucoma surgery for the majority of patients."

Oral and Paper Presentations: TearCare System

• Impact of TearCare on reading speed in patients with dry eye disease oral presentation by Preeya Gupta, MD.
• Localized heat therapy (LHT) outcomes for meibomian gland dysfunction (MGD): A three study synthesis poster presentation by Jennifer Loh, MD.

"The research being presented at ASCRS continues to highlight the significant impact MGD has on visual function and the clinical benefit of meaningful treatment of MGD with precision heat and manual expression of the meibomian glands provided using the TearCare System technology,” said Preeya K. Gupta, MD founder of Triangle Eye Consultants of Raleigh North Carolina.

Sight Sciences will also provide additional peer-to-peer educational opportunities by hosting a series of interactive panel discussions during the exhibition. Twelve ophthalmic physicians from various practice settings will discuss their unique insights and experiences using the Omni Surgical System as a standalone (not in combination with cataract surgery) minimally invasive glaucoma surgery (MIGS) treatment. All registered attendees are invited to attend the Omni Speaker Forum at the Sight Sciences booth.

OMNI Speaker Forum at ASCRS (Booth 1124)

Saturday, May 6, 2023

• 10 AM PDT: Nine Reasons Why We Perform MIGS with OMNI (Neda Shamie, MD; Philip Ngai, MD; Noureen Khan, MD)
• 1:30 PM PDT: Standalone MIGS: What Are You Waiting For? (Jai Parekh, MD, MBA; Christine Funke, MD; Douglas McGraw, MD)

Sunday, May 7, 2023

• 11:30 AM PDT: MIGS Beyond Cataract Surgery: An Interventional Mindset (Ike Ahmed, MD; Felise May Barte, MD; Lawrence Woodward, MD)
• 1 PM PDT: OMNI Surgical System: What the Data Says (Sameh Mosaed, MD; Shamik Bafna, MD; Syril Dorairaj, MD)

Physicians participating in the Speaker Forum are paid consultants of Sight Sciences. Visit omnisurgical.com/ascrs for more details.